Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,003 public trials 2,033 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

NCT01090921

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Little Rock VA Medical Center Little Rock, Arkansas, United States
  • West Los Angeles VA Medical Center Los Angeles, California, United States
  • San Francisco VA Medical Center San Francisco, California, United States
  • Eastern Colorado Health Care System Denver, Colorado, United States
View Trial Details
Completed

Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma

NCT02590263

Conditions
Astrocytoma, Glioblastoma, Glioblastoma Multiforme, +17 more
Locations
  • Nagoya University Hospital /ID# 138559 Nagoya, Aichi-ken, Japan
  • Hiroshima University Hospital /ID# 139399 Hiroshima, Japan
  • Hokkaido University Hospital /ID# 150589 Sapporo, Hokkaido, Japan
  • University of Tsukuba Hospital /ID# 140433 Tsukuba, Ibaraki, Japan
View all 22 locations
View Trial Details
Completed

A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma

NCT00718419

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Boston, Massachusetts, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. La Roche-sur-Yon, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Nantes, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Nîmes, France
View Trial Details
Completed

A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

NCT02945215

Conditions
B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Beijing cancer hospital Beijing, Beijing Municipality, China
  • Peking University third hospital Beijing, Beijing Municipality, China
  • The 307th Hospital of Military Medical Sciences Beijing, Beijing Municipality, China
  • Harbin Medical University Cancer Hospital Haerbin, Heilongjiang, China
View Trial Details

Related conditions